Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
- PMID: 29315510
- PMCID: PMC5947521
- DOI: 10.1002/cpt.1010
Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
Abstract
There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug development decisions. While a true surrogate marker for mortality in heart failure (HF) remains elusive, the successes and failures of previous trials can reveal markers that support clinical Go/NoGo decisions.
© 2018 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
Figures
References
-
- Ponikowski, P . et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 18, 891–975 (2016). - PubMed
-
- Yancy, C.W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62, e147–239 (2013). - PubMed
-
- Braunschweig, F. , Cowie, M.R. & Auricchio, A. What are the costs of heart failure? Europace 13(suppl. 2), ii13–17 (2011). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
